Effectiveness of Anticonvulsants Compared to Antidepressants in Reducing Pain in Diabetic Neuropathy Complications
Isi Artikel Utama
Abstrak
Diabetes mellitus is a non-communicable disease which is a global challenge. Diabetes that is chronic and uncontrolled can cause various complications, one of which is diabetic neuropathy. One of the most common complications is neuropathy pain or painful diabetic peripheral neuropathy (DPN), at least 25% - 30% of people with diabetes mellitus experience diabetic neuropathy pain. Diabetic neuropathy pain can interfere with work or daily activities, so treatment is necessary. Through this literature review, we will conduct an assessment of effective pharmacological therapy in reducing or alleviating diabetic neuropathy pain. The classes of drugs under review are anticonvulsants (carbamazepine, gabapentin, and pregabalin) and antidepressants (amitriptyline and duloxetine). This type of literature review is narrative review, the database used to search for literature sources, namely, PubMed, PMC, and Google Scholar uses keywords, the search results are limited to articles published between 2012 and 2022, free full text using Indonesian or Indonesian. English. Based on a review of the literature, the pregabalin group had the best efficacy, and the number of evidence-based medicines used pregabalin, followed by duloxetine, amitriptyline, and gabapentin. The most common side effects found in all types of drugs reviewed were dizziness, headache, nausea, and vomiting. However, it should be noted that in some groups there was decreased consciousness or somnolence, constipation, and anorexia.
Rincian Artikel
Referensi
International Diabetes Federation. IDF Diabetes Atlas, the Seventh Edition [Internet]. 7th ed. Cavan D, Fernandes J da R, Makaroff L, Ogurtsova K, Webber S, editors. 2015. 1–140 p. Available from: http://www.diabetesatlas.org/resources/2015-atlas.html
Snyder MJ, Gibbs LM, Lindsay TJ. Treating painful diabetic peripheral neuropathy: An update. Am Fam Physician. 2016;94(3):227–34.
Pop-Busui R, Boulton AJM, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic neuropathy: A position statement by the American diabetes association. Diabetes Care. 2017;40(1):136–54.
Ang L, Cowdin N, Mizokami-Stout K, Pop-Busui R. Update on the management of diabetic neuropathy. Diabetes Spectr. 2018;31(3):224–33.
Khdour MR. Treatment of diabetic peripheral neuropathy: a review. J Pharm Pharmacol. 2020;72(7):863–72.
Kementerian Kesehatan Republik Indonesia. PEDOMAN NASIONAL PELAYANAN KEDOKTERAN TATA LAKSANA DIABETES MELITUS TIPE 2 DEWASA. In 2020. p. 183.
Fornasari D. Pharmacotherapy for Neuropathic Pain: A Review. Pain Ther. 2017;6(s1):25–33.
Sankar V, OOmmen AE, Thomas A, Nair J V., James JS. Efficacy , Safety and Cost Effectiveness of Amitriptyline and Pregabalin in Patients with Diabetic Peripheral Neuropathy. 2017;(January 2017). Available from: https://www.ijpsonline.com/articles/efficacy-safety-and-cost-effectiveness-of-amitriptyline-and-pregabalin-in-patients-with-diabetic-peripheral-neuropathy-3372.html#a1
Boyle J, Eriksson MEV, Gribble L, Gouni R, Johnsen S, Coppini D V., et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: Impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care [Internet]. 2012;35(12):2451–8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507552/
Putra I, Anwar Y, Surbakti KP. Perbedaan Efek Analgesik Amitriptilin, Gabapentin, Dan Pregabalin Pada Neuropati Diabetik Dan Neuralgia Trigeminal. Maj Kedokt Neurosains Perhimpun Dr Spes Saraf Indones. 2018;35(2):109–15.
Alvarado AM, Navarro SA. Clinical Trial Assessing the Efficacy of Gabapentin Plus B Complex ( B1 / B12 ) versus Pregabalin for Treating Painful Diabetic Neuropathy. 2016;2016.
Daniel SR, Badyal DK, Jacob JJ, Kaur J. Efficacy and safety of pregabalin versus amitriptyline in patients with painful diabetic neuropathy. Int J Adv Med. 2018;5(3):716.
Tremont-Lukats IW, Megeff C, Backonja M-M. Anticonvulsants for Neuropathic Pain Syndromes. Drugs. 2000;60(5):1029–52.
Mm R, Rk K, Rizvi AN, Arifuzzaman M, Sharif A, Khanam S. Comparison of Carbamazipine and Amitryptyline for the Reduction of Diabetic Neuropathic Pain?: A Randomized Clinical Trial. 2017;33(1):6–12.
Razazian N, Baziyar M, Moradian N, Afshari D, Bostani A, Mahmoodi M. Evaluation of the efficacy and safety of pregabalin, venlafaxine, and carbamazepine in patients with painful diabetic peripheral neuropathy A randomized, double-blind trial [Internet]. Vol. 19, Neurosciences. 2014. Available from: www.neurosciencesjournal.org
Saeed T, Nasrullah M, Ghafoor A, Shahid R, Islam N, Usman M, et al. Efficacy and tolerability of carbamazepine for the treatment of painful diabetic neuropathy in adults?: a 1 2-week , open-label , multicenter study. 2014;339–43. Available from: https://pubmed.ncbi.nlm.nih.gov/25061334/
Qureshi Z, Ali MN, Khalid M. An Insight into Potential Pharmacotherapeutic Agents for Painful Diabetic Neuropathy. J Diabetes Res. 2022;2022(Dm).
Roy MK, Kuriakose AS, Varma SK, Jacob LA, Beegum NJ. A study on comparative efficacy and cost effectiveness of Pregabalin and Duloxetine used in diabetic neuropathic pain. Diabetes Metab Syndr Clin Res Rev [Internet]. 2017;11(1):31–5. Available from: http://dx.doi.org/10.1016/j.dsx.2016.07.003
Majdinasab N, Kaveyani H, Azizi M. A comparative double-blind randomized study on the effectiveness of Duloxetine and Gabapentin on painful diabetic peripheral polyneuropathy. 2019;1985–92.
Tesfaye S, Wilhelm S, Lledo A, Schacht A, Tölle T, Bouhassira D, et al. Duloxetine and pregabalin?: High-dose monotherapy or their combination?? The ‘“ COMBO-DN study ”’ – a multinational , randomized , double-blind , parallel-group study in patients with diabetic peripheral neuropathic pain. Pain [Internet]. 2013;154(12):2616–25. Available from: http://dx.doi.org/10.1016/j.pain.2013.05.043
Pandey A, Sompura S, Pandey S, Chaturvedi M, Maheshwari PK, Kumar S. Double-blind randomized placebo-controlled trial to compare the effects of gabapentin, pregabalin and tramadol + acetaminophen combination in improvement of pain in patients with painful diabetic neuropathy. Int J Diabetes Dev Ctries. 2015;35:389–92.
Zhulhajsyirah, Wahyudin E, Tammas J. Efektivitas Dan Efek Samping Penggunaan Gabapentin Pada Pasien Neuropati Diabetik Di Rsup Dr. Wahidin Sudirohusodo Makassar. Maj Farm dan Farmakol. 2018;22(2):44–7.
Parsons B, Li C, Emir B, Vinik AI. The efficacy of pregabalin for treating pain associated with diabetic peripheral neuropathy in subjects with type 1 or type 2 diabetes mellitus. Curr Med Res Opin. 2018;34(11):2015–22.
Arshad I, Zulfiqar H, Shafi B. To Compare the Efficacy of Pregabalin and Amitriptyline for Pain Relief in Patients with Diabetic Peripheral Neuropathy. 2018;8(2):21–5.
Joharchi K, Memari M, Azargashb E, Saadat N. Efficacy and safety of duloxetine and Pregabalin in Iranian patients with diabetic peripheral neuropathic pain?: a double-blind , randomized clinical trial. 2019;575–82.
MU Y, LIU X, LI Q, CHEN K, LIU Y, LV X, et al. Efficacy and safety of pregabalin for painful diabetic peripheral neuropathy in a population of Chinese patients: a randomized, placebo-controlled trial. Pap Knowl Towar a Media Hist Doc. 2014;
Shahid W, Kumar R, Shaikh A, Kumar S, Jameel R, Fareed S. Comparison of the Efficacy of Duloxetine and Pregabalin in Pain Relief Associated with Diabetic Neuropathy. 2019;
World Health Organization (WHO). 2020. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death